Trials with a site in Mexico City, Mexico City

This study wants to measure the long-term safety and how well it works of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase.

NCT03486873 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

Main Objective of this study is to examine long-term safety of nivolumab this drug alone including combinations and other cancer therapies in various tumor types.

NCT03899155 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and in combination with endocrine therapy. Part 1 includes dose escalation cohorts evaluating PF-07220060 as single agent or in combination with endocrine therapy or enzalutamide, as well as a food effect cohort and a DDI cohort.

NCT04557449 · Official ClinicalTrials.gov record · Pfizer

The purpose of this pediatric study is to measure the drug levels, how well it works and safety of Deucravacitinib in children and adolescent participants aged 4 to \<18 years with moderate to severe plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to \<18 years) and Cohort 2 (age 4 to \<12 years), with two parts; for each cohort.

NCT04772079 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

This study examines how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is the type of treatment that helps the body's immune system fight cancer.

NCT04871542 · Official ClinicalTrials.gov record · SWOG Cancer Research Network

This phase II, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study is designed to measure the safety, how well it works and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to \<12 with LN.

NCT05039619 · Official ClinicalTrials.gov record · Hoffmann-La Roche

The primary objective is to measure the how well it works of carisbamate (YKP509) as added on top of your current treatment treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with dummy treatment (placebo) in pediatric and adult subjects (age 4-55 years) diagnosed with Lennox Gastaut Syndrome (LGS).

NCT05219617 · Official ClinicalTrials.gov record · SK Life Science, Inc.

This is a Phase 3, multicenter, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study to measure the clinical how well it works, safety, and tolerability of XEN1101 administered as added on top of your current treatment treatment in primary generalized tonic-clonic seizures (PGTCS).

NCT05667142 · Official ClinicalTrials.gov record · Xenon Pharmaceuticals Inc.

This study aims to compare the how well it works of vericiguat versus dummy treatment (placebo) on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to dummy treatment (placebo) in reducing NT-proBNP at Week 16 of the Base Period.

NCT05714085 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

The X-TOLE3 Phase 3 clinical trial is a randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study that will measure the clinical how well it works, whether it is safe and how hard side effects are to live with of XEN1101 administered as added on top of your current treatment therapy in focal-onset seizures.

NCT05716100 · Official ClinicalTrials.gov record · Xenon Pharmaceuticals Inc.

The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.

NCT05920356 · Official ClinicalTrials.gov record · Amgen

To assess the how well it works and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids.

NCT06023589 · Official ClinicalTrials.gov record · AstraZeneca

This is a phase III, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, multi-center, global study to explore the how well it works and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.

NCT06079671 · Official ClinicalTrials.gov record · AstraZeneca

This study wants to evaluate long-term whether it is safe and how hard side effects are to live with of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).

NCT06133972 · Official ClinicalTrials.gov record · Novartis Pharmaceuticals

This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, parallel-group studies in patients with ADP * Substudy 1 (Phase 2) will evaluate how well it works and dose response of ACP-204 30 and 60 mg vs dummy treatment (placebo). * Substudies 2A and 2B (both: Phase 3) will be confirmatory studies of either both doses (ACP-204 30 and 60 mg, respectively) or a single dose from Part 1 vs dummy treatment (placebo).

NCT06159673 · Official ClinicalTrials.gov record · ACADIA Pharmaceuticals Inc.

The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respect to OS.

NCT06170788 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

This is a multi-center evaluation of efruxifermin (EFX) in a randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study in subjects with non-cirrhotic NASH/MASH and fibrosis stage 2 or 3 (F2 or F3). The study will enroll subjects in two cohorts for a total samples size of 1650 subjects.

NCT06215716 · Official ClinicalTrials.gov record · Akero Therapeutics, Inc

The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.

NCT06252649 · Official ClinicalTrials.gov record · Amgen

This is a Phase III, international, multi-centre, randomly assigned, neither you nor the study doctors know who gets the real treatment, parallel-group, double-dummy, active-controlled, event-driven study in patients with chronic HF and impaired kidney function who had a recent HF event. The aim is to measure the effect of balcinrenone/dapagliflozin vs dapagliflozin, given once daily on top of other classes of SoC, on CV death and HF events.

NCT06307652 · Official ClinicalTrials.gov record · AstraZeneca

The study will assess the how well it works and safety of 2 dose regimens of pegozafermin compared to dummy treatment (placebo) for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.

NCT06318169 · Official ClinicalTrials.gov record · Hoffmann-La Roche

This is a study evaluating the how well it works and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There is one primary study hypothesis: Combination of calderasib and pembrolizumab is superior to dummy treatment (placebo) plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

NCT06345729 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

The study will assess the how well it works and safety of pegozafermin administered in participants with biopsy-confirmed and clinically confirmed compensated cirrhosis due to MASH .

NCT06419374 · Official ClinicalTrials.gov record · Hoffmann-La Roche

The purpose of this protocol is to measure the how well it works and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to dummy treatment (placebo) in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 52 (US/FDA and EU/EMA), and that at least 1 tulisokibart dose level is superior to dummy treatment (placebo) in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA).

NCT06430801 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

This is a multi-center evaluation of efruxifermin (EFX) in a randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment study in subjects with compensated cirrhosis due to NASH/MASH.

NCT06528314 · Official ClinicalTrials.gov record · Akero Therapeutics, Inc

This study wants to measure the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.

NCT06617325 · Official ClinicalTrials.gov record · UCB Biopharma SRL

This study is open to adults who are at least 18 years old living with obesity and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH) and * moderate or advanced liver fibrosis People with a history of acute or chronic liver diseases other than MASH or chronic alcohol intake cannot take part in this study. this study wants to find out whether a medicine called survodutide helps people with MASH and moderate or advanced liver fibrosis improve their liver function.

NCT06632444 · Official ClinicalTrials.gov record · Boehringer Ingelheim

This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * body-mass index (BMI) of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study.

NCT06632457 · Official ClinicalTrials.gov record · Boehringer Ingelheim

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs.

NCT06671483 · Official ClinicalTrials.gov record · Takeda

Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screening period to facilitate sites' identification of potentially eligible participants to enter the full screening assessments.

NCT06677060 · Official ClinicalTrials.gov record · AstraZeneca

This study wants to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

NCT06717347 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

This is a Phase 3, open-label, randomly assigned, clinical trial evaluating the how well it works and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.

NCT06757634 · Official ClinicalTrials.gov record · Celcuity Inc

This 24-month study will assess the long-term safety and how well it works of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.

NCT06807281 · Official ClinicalTrials.gov record · Pfizer

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

NCT06824467 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.

NCT06841354 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

The purpose of this Phase 3b study is to assess the how well it works, whether it is safe and how hard side effects are to live with of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).

NCT06846281 · Official ClinicalTrials.gov record · Novartis Pharmaceuticals

This clinical trial is designed to assess the how well it works and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have HER2-overexpressing and PD-L1 TPS \<50% without known AGA that have locally available therapies targeting their AGAs in first-line advanced/metastatic setting.

NCT06899126 · Official ClinicalTrials.gov record · Daiichi Sankyo

Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Zolbetuximab with chemotherapy may be used to treat stomach and GEJ cancer when the cancer cells do not have a protein called HER2 (human epidermal growth factor receptor 2) on their surface (HER2-negative) but do have a protein called Claudin 18.2 (Claudin 18.2-positive).

NCT06901531 · Official ClinicalTrials.gov record · Astellas Pharma Global Development, Inc.

The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and dummy treatment (placebo), leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment.

NCT06937086 · Official ClinicalTrials.gov record · Eli Lilly and Company

The main purpose of this study is to measure the how well it works and safety of mirikizumab and dummy treatment (placebo) compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.

NCT06937099 · Official ClinicalTrials.gov record · Eli Lilly and Company

This study wants to measure the how well it works, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis

NCT06979453 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

This study wants to measure the how well it works and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

NCT07011732 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure.

NCT07064473 · Official ClinicalTrials.gov record · Boehringer Ingelheim

Chronic Obstructive Pulmonary Disease is a leading cause of global morbidity and mortality, especially in low- and middle-income countries. Exacerbations accelerate disease progression and increase the risk of death.

NCT07069829 · Official ClinicalTrials.gov record · AstraZeneca

In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread. This study specifically aims to evaluate how well Ris-Rez works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether Ris-Rez makes cancers smaller or disappear completely and if it helps participants live longer.

NCT07099898 · Official ClinicalTrials.gov record · GlaxoSmithKline

A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

NCT07100080 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

A study to measure the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis

NCT07116967 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

This open label, single arm study will measure the PK and PD effects of fenebrutinib in children and adolescents with RMS aged between 10 and \< 18 years. This study consists of a Dose Exploration Period and an Optional Extension Period.

NCT07161258 · Official ClinicalTrials.gov record · Hoffmann-La Roche

The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD based on non-invasive tests (NITs), which indicate they are more likely to develop MALO.

NCT07165028 · Official ClinicalTrials.gov record · Eli Lilly and Company

This study wants to measure the how well it works, safety, and pharmacokinetics (PK) of prasinezumab compared with dummy treatment (placebo) in participants with early-stage Parkinson's disease (PD) on stable symptomatic this drug alone with levodopa.

NCT07174310 · Official ClinicalTrials.gov record · Hoffmann-La Roche

The main purpose of the study is to measure the effectiveness and safety of LY4268989 when given with mirikizumab compared to mirikizumab alone in adult participants with moderately to severely active ulcerative colitis (UC). Study participation will last approximately 118 weeks, including 104 weeks of treatment and may include up to 21 visits.

NCT07186101 · Official ClinicalTrials.gov record · Eli Lilly and Company

Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation.

NCT07190248 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose tumors have activating HER2 tyrosine kinase domain (TKD) mutations. Eligible participants must have undergone curative-intent surgery and received guideline-appropriate perioperative systemic therapy, either neoadjuvant platinum-based chemotherapy with or without immunotherapy, or adjuvant platinum-based chemotherapy.

NCT07195695 · Official ClinicalTrials.gov record · Boehringer Ingelheim

Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb).

NCT07216703 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

This study wants to measure the safety and how well it works of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma

NCT07221149 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

A randomly assigned, Active-Controlled, neither you nor the study doctors know who gets the real treatment, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer(HARMONi-GI3)

NCT07228832 · Official ClinicalTrials.gov record · Summit Therapeutics

This study wants to measure cardiovascular outcomes with orforglipron compared with dummy treatment (placebo) in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

NCT07241390 · Official ClinicalTrials.gov record · Eli Lilly and Company

This study wants to assess the how well it works and safety of brenipatide when administered with standard of care (SoC), compared with dummy treatment (placebo) plus SoC in delaying the worsening of bipolar disorder symptoms. The trial is divided into three periods as follows: Screening period that will last approximately 1 month, treatment period that will last a minimum of 6 months, and the follow up period that will last approximately 2 months.

NCT07286175 · Official ClinicalTrials.gov record · Eli Lilly and Company

This study will measure the how well it works and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) who have received one prior second-generation ARPi.

NCT07287150 · Official ClinicalTrials.gov record · Hoffmann-La Roche

This phase III, neither you nor the study doctors know who gets the real treatment, multi-center treat-through study will measure the how well it works and safety of Afimkibart (also known as RO7790121) in children with moderately to severely active Crohn's Disease (CD).

NCT07298421 · Official ClinicalTrials.gov record · Hoffmann-La Roche

This study is open to adults with systemic lupus erythematosus (SLE). this study wants to find out whether a medicine called BI 3000202 helps people with SLE.

NCT07409181 · Official ClinicalTrials.gov record · Boehringer Ingelheim

This study evaluates the safety and how well it works of brenipatide when administered with standard of care (SoC) compared to dummy treatment (placebo) plus SoC in delaying the return of major depressive symptoms. The trial is divided into four periods as follows: a screening period that will last approximately 1 month, a treatment period with a potential post treatment period that combined will last a minimum of 12 months, and the follow up period that will last approximately 2 months.

NCT07412756 · Official ClinicalTrials.gov record · Eli Lilly and Company

The main purpose of this study is to measure the safety and effectiveness of LY4268989 when compared to dummy treatment (placebo) in adult participants with moderately to severely active ulcerative colitis (UC). The study drug will be administered orally.

NCT07415044 · Official ClinicalTrials.gov record · Eli Lilly and Company

This study wants to evaluate how well nipocalimab works as compared to dummy treatment (placebo) in participants with moderate to severe Systemic lupus erythematosus (SLE, a long-term disease where the immune system mistakenly attacks its own healthy tissues, causing swelling and redness in various organs).

NCT07438496 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC

This study is open to adults with advanced extrapulmonary neuroendocrine cancer. this study wants to find out if a study medicine called obrixtamig plus standard chemotherapy (carboplatin and etoposide) improves survival when compared to standard chemotherapy (carboplatin and etoposide) alone.

NCT07544654 · Official ClinicalTrials.gov record · Boehringer Ingelheim

This study wants to evaluate how well brenipatide (LY3537031) is tolerated, what side effects may occur, and the safety and how well it works in participants with Irritable Bowel Syndrome-Diarrhea (IBS-D). The study drug will be administered subcutaneously (SC) (under the skin) when compared with dummy treatment (placebo).

NCT07545759 · Official ClinicalTrials.gov record · Eli Lilly and Company

This study wants to evaluate how well brenipatide (LY3537031) is tolerated what side effects may occur, and the safety and how well it works in participants with Irritable Bowel Syndrome-Constipation (IBS-C). The study drug will be administered subcutaneously (SC) (under the skin) when compared with dummy treatment (placebo).

NCT07545772 · Official ClinicalTrials.gov record · Eli Lilly and Company

The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight.

NCT07595549 · Official ClinicalTrials.gov record · Pfizer

This study wants to measure the how well it works, whether it is safe and how hard side effects are to live with of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered orally once daily in addition to SoC. This is a population with high unmet medical need and an increased risk of CKD progression, who are frequently excluded from treatment trials.

NCT07624305 · Official ClinicalTrials.gov record · AstraZeneca

This study compares the how well it works, whether it is safe and how hard side effects are to live with of CAB ULA and RPV ULA administered with CAB long acting (LA) and RPV LA administered in adults and adolescents with HIV who are virologically suppressed on anti-retroviral therapy (ART).

NCT07650916 · Official ClinicalTrials.gov record · ViiV Healthcare

This study wants to measure the how well it works, safety, and tolerability of elecoglipron, compared with dummy treatment (placebo) in adults with type 2 diabetes mellitus (T2DM) and impaired renal function, who are or will be on a background of sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin 10 mg as per guideline directed medical therapy (GDMT) for chronic kidney disease (CKD). Additionally, participants are on other glucose-lowering medication(s).

NCT07662135 · Official ClinicalTrials.gov record · AstraZeneca

Researchers want to understand what happens to muscle and fat in the body after adults with obesity and/or type 2 diabetes start taking a GLP-1 receptor agonist medication (GLP-1RA), a type of drug already approved and commonly prescribed for weight loss and blood sugar control. No experimental medication will be given.

NCT07835360 · Official ClinicalTrials.gov record · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran